NIH Grants

Development of Ultra Long-Acting Oral HIV Therapies

Grant Source:

Non-adherence to anti-retroviral therapy by HIV+ patients results in increased viral loads and risk of emergence of drug-resistant HIV strains. This poses a major public health threat. Lyndra Co. has developed an orally available, long-acting drug delivery system that it will now formulate to deliver anti-retrovirals.

Tags:

NIH

Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles

Grant Source:

NIH

Project Narrative In this application we propose to utilize novel synthetic chemistry to develop a series of aliphatic tenofovir prodrugs designed to greatly enhance cellular uptake and to provide prolonged intracellular exposure to molecules with potent antiviral activity.

Tags:

NIH

Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01)

Grant Source:

NIH

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention.

Tags: